OP.6C.05] THE POSSIBILITY OF IMPROVING THE COMPLIANCE TO THE TREATMENT BY USING OF ELECTRONIC VERSION OF SCORE IN HYPERTENSIVE PATIENTS

Abstract

Objective: It is well-known that pts without signs of atherosclerotic disease are weakly motivated to drug treatment. We suggested that vivid demonstration to the pts their real risk and its favorable changes if achieving goals of therapy using electronic version of SCORE (EV SCORE) would lead to better motivation and compliance to drug treatment in hypertensive pts. Design and method: 140 hypertensive males aged 40–55 with high risk according to SCORE evaluation (all of them were smokers and had high level of total cholesterol - more than 5 mmol/l) and without signs of atherosclerotic disease were included in the trial. They were randomly divided in two groups by 70 pts in each. In one group total risk was calculated by using EV SCORE (main group). In the second group total risk was evaluated by chart version of SCORE (reference group). In both groups pts were shown not only initial risk but its change if achieving goals of therapy. All pts as high risk ones were prescribed antihypertensive and lipid-lowering drugs as well as healthy life-style recommendations during 9 months. Results: Compliance to both antihypertensive and lipid lowering therapy was significantly higher in the group where EV SCORE was used. In this group 46 pts out of 70 (65,7%) remained on antihypertensive drugs by the end of the study, while only 35 pts (50,0%) - in reference group, p < 0,05. The difference especially was pronounced concerning lipid- lowering treatment. The percentage of pts who remained on lipid- lowering drugs by the end of the study was significantly higher in the main group comparing with the reference group – respectively 42 pts (60,0%) and 12 pts (17,1%), p < 0,001. As a result more pts in the main group achieved blood pressure and lipid variables goals, then in the reference group. Conclusions: Results show, that using EV SCORE in clinical practice allows not only quick evaluation of total risk but also motivates hypertensive pts without signs of atherosclerotic disease to better compliance to antihypertensive and lipid-lowering therapy.